Literature DB >> 19948444

Perioperative search for circulating tumor cells in patients undergoing radical cystectomy for bladder cancer.

A Karl1, S Tritschler, S Hofmann, C G Stief, C Schindlbeck.   

Abstract

OBJECTIVE: Despite having an organ confined tumor stage at the time of radical cystectomy, a certain number of bladder cancer patients will develop local or distant metastases over time. Currently there are no reliable serum markers for monitoring and evaluating risk profiles of urothelial cancers. Several studies suggest that detection of Circulating Tumor Cells (CTC) may correlate with disease status and prognosis at baseline and early in the treatment of cancers. The presence of CTCs in whole blood before and during radical cystectomy could provide further information on disease status, and could be used as an indicator to determine the need for adjuvant or even perioperative chemotherapy.
METHODS: From 03/2009 to 05/2009, five patients with histologically proven transitional cell carcinoma of the urinary bladder participated in this study. All patients were admitted to the hospital for radical cystectomy (rCx). A standard or extended lymph node dissection was performed in all cases. Preoperative CT or MRI scans revealed no distant or local metastases. Median age was 66.8 years (55-81 yrs). After obtaining informed consent from each patient, approximately 30 mL of peripheral blood was taken immediately before rCx and again during surgical removal of the urinary bladder from the patients ' body. As additional parameters, operation time (OR) for surgical removal of the bladder and the amount of blood volume that was used for the detection of CTCs were recorded. Obtained blood samples were processed using the Cell-Search System (Veridex) within 48 hours of collection. CTCs were identified and quantitated using the Cell-Search System, followed by re-evaluation of the provided results by specially trained and experienced personal (CS, SH).
RESULTS: CTCs were detected before and during surgical removal of the urinary bladder in one of five patients (20%). In the one patient positive for CTC, two CTCs were detected in the blood sample that was obtained before surgery (analyzed blood volume was 25 mL). There was one CTC detected in the blood sample that was obtained during surgical removal of the urinary bladder (analyzed blood volume was 27 mL).There was no rise in the amount of CTCs during surgical procedure. The final pathological report of this patient showed an advanced tumor stage (T3b, N0, R1). In the other patients, no CTCs were detected at all, neither before rCX nor right after surgical removal of the bladder. Pathological stage for these patients ranged from pT1m G3 - pT2b G3. None of these patients showed lymph node involvement. An average of 14.6 lymph nodes (5-40 LNs) were obtained. OR time to surgical removal of the urinary bladder ranged from 60 minutes to 150 minutes (mean 82 min.).
CONCLUSIONS: Although only a very small group of patients was analyzed in this study, the presence of CTCs seems to be correlated with an advanced tumor stage. Therefore the detection of CTCs could be used for an optimized assessment of a patient's disease status in urothelial cancer. A further aim of this study was to assess whether surgical manipulation during radical cystectomy is associated with a release of CTCs into the vascular system. None of the patients who were negative for CTCs before surgery showed CTCs during surgical removal of the bladder, suggesting that there was no release of CTCs during surgery. However, further study is needed to prove these findings and evaluate the significance of CTCs as an indicator for therapeutic decisions.

Entities:  

Mesh:

Year:  2009        PMID: 19948444      PMCID: PMC3352289          DOI: 10.1186/2047-783x-14-11-487

Source DB:  PubMed          Journal:  Eur J Med Res        ISSN: 0949-2321            Impact factor:   2.175


  19 in total

1.  Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1,026 cases.

Authors:  M A Ghoneim; M M el-Mekresh; M A el-Baz; I A el-Attar; A Ashamallah
Journal:  J Urol       Date:  1997-08       Impact factor: 7.450

2.  Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer.

Authors:  G Thomas Budd; Massimo Cristofanilli; Mathew J Ellis; Allison Stopeck; Ernest Borden; M Craig Miller; Jeri Matera; Madeline Repollet; Gerald V Doyle; Leon W M M Terstappen; Daniel F Hayes
Journal:  Clin Cancer Res       Date:  2006-11-01       Impact factor: 12.531

3.  Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer.

Authors:  Daniel C Danila; Glenn Heller; Gretchen A Gignac; Rita Gonzalez-Espinoza; Aseem Anand; Erika Tanaka; Hans Lilja; Lawrence Schwartz; Steven Larson; Martin Fleisher; Howard I Scher
Journal:  Clin Cancer Res       Date:  2007-12-01       Impact factor: 12.531

4.  Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer.

Authors:  David R Shaffer; Margaret A Leversha; Daniel C Danila; Oscar Lin; Rita Gonzalez-Espinoza; Bin Gu; Aseem Anand; Katherine Smith; Peter Maslak; Gerald V Doyle; Leon W M M Terstappen; Hans Lilja; Glenn Heller; Martin Fleisher; Howard I Scher
Journal:  Clin Cancer Res       Date:  2007-04-01       Impact factor: 12.531

5.  Detection of circulating urothelial cancer cells in the blood using the CellSearch System.

Authors:  Michio Naoe; Yoshio Ogawa; Jun Morita; Kei Omori; Kumiko Takeshita; Takeshi Shichijyo; Taisuke Okumura; Atsushi Igarashi; Atsushi Yanaihara; Sanju Iwamoto; Takashi Fukagai; Akira Miyazaki; Hideki Yoshida
Journal:  Cancer       Date:  2007-04-01       Impact factor: 6.860

6.  Bladder carcinoma as a systemic disease.

Authors:  G R Prout; P P Griffin; W U Shipley
Journal:  Cancer       Date:  1979-06       Impact factor: 6.860

7.  Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables.

Authors:  J Sastre; M L Maestro; J Puente; S Veganzones; R Alfonso; S Rafael; J A García-Saenz; M Vidaurreta; M Martín; M Arroyo; M T Sanz-Casla; E Díaz-Rubio
Journal:  Ann Oncol       Date:  2008-01-22       Impact factor: 32.976

8.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

9.  Detection of circulating tumor cells in patients with urothelial cancer.

Authors:  D J Gallagher; M I Milowsky; N Ishill; A Trout; M G Boyle; J Riches; M Fleisher; D F Bajorin
Journal:  Ann Oncol       Date:  2008-10-03       Impact factor: 32.976

10.  Immunomagnetic enrichment of disseminated tumor cells in bone marrow and blood of breast cancer patients by the Thomsen-Friedenreich-Antigen.

Authors:  Christian Schindlbeck; Julia Stellwagen; Udo Jeschke; Uwe Karsten; Brigitte Rack; Wolfgang Janni; Julia Jückstock; Augustinos Tulusan; Harald Sommer; Klaus Friese
Journal:  Clin Exp Metastasis       Date:  2008-01-10       Impact factor: 5.150

View more
  15 in total

Review 1.  Challenges in circulating tumor cell detection by the CellSearch system.

Authors:  Kiki C Andree; Guus van Dalum; Leon W M M Terstappen
Journal:  Mol Oncol       Date:  2015-12-25       Impact factor: 6.603

2.  Detection of circulating tumor cells in metastatic and clinically localized urothelial carcinoma.

Authors:  Thomas W Flaig; Shandra Wilson; Adrie van Bokhoven; Marileila Varella-Garcia; Pamela Wolfe; Paul Maroni; E Erin Genova; Diana Morales; M Scott Lucia
Journal:  Urology       Date:  2011-08-02       Impact factor: 2.649

3.  Application of a telomerase-based circulating tumor cell (CTC) assay in bladder cancer patients receiving postoperative radiation therapy: a case study.

Authors:  Melody Ju; Gary D Kao; David Steinmetz; Sanjay Chandrasekaran; Stephen M Keefe; Thomas J Guzzo; John P Christodouleas; Stephen M Hahn; Jay F Dorsey
Journal:  Cancer Biol Ther       Date:  2014-03-11       Impact factor: 4.742

4.  In vitro culturing of viable circulating tumor cells of urinary bladder cancer.

Authors:  Martin Cegan; Katarina Kolostova; Rafal Matkowski; Marek Broul; Jan Schraml; Marek Fiutowski; Vladimir Bobek
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

5.  Leukocyte-adjusted epigenome-wide association studies of blood from solid tumor patients.

Authors:  Scott M Langevin; E Andres Houseman; William P Accomando; Devin C Koestler; Brock C Christensen; Heather H Nelson; Margaret R Karagas; Carmen J Marsit; John K Wiencke; Karl T Kelsey
Journal:  Epigenetics       Date:  2014-03-26       Impact factor: 4.528

Review 6.  [Tumor cells in the peripheral blood of patients with urothelial carcinoma of the bladder: detection and impact of circulating].

Authors:  M Rink; A Soave; O Engel; M Fisch; S Riethdorf; K Pantel
Journal:  Urologe A       Date:  2014-04       Impact factor: 0.639

Review 7.  Do circulating tumor cells have a role in deciding on adjuvant chemotherapy after radical cystectomy?

Authors:  Armin Soave; Sabine Riethdorf; Klaus Pantel; Margit Fisch; Michael Rink
Journal:  Curr Urol Rep       Date:  2015-07       Impact factor: 3.092

Review 8.  The current role and future directions of circulating tumor cells and circulating tumor DNA in urothelial carcinoma of the bladder.

Authors:  Michael Rink; Heidi Schwarzenbach; Sabine Riethdorf; Armin Soave
Journal:  World J Urol       Date:  2018-10-26       Impact factor: 4.226

Review 9.  Diagnostic value of circulating tumor cell detection in bladder and urothelial cancer: systematic review and meta-analysis.

Authors:  Pavlos Msaouel; Michael Koutsilieris
Journal:  BMC Cancer       Date:  2011-08-04       Impact factor: 4.430

10.  Clinical Significance of Early Changes in Circulating Tumor Cells from Patients Receiving First-Line Cisplatin-Based Chemotherapy for Metastatic Urothelial Carcinoma.

Authors:  Emanuela Fina; Andrea Necchi; Patrizia Giannatempo; Maurizio Colecchia; Daniele Raggi; Maria Grazia Daidone; Vera Cappelletti
Journal:  Bladder Cancer       Date:  2016-10-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.